Lakefront Biotherapeutics NV

Galapagos NV is a biotechnology enterprise focused on discovering, acquiring, and advancing therapeutics for patients suffering from serious conditions. Operating as a single business segment, the organization concentrates its development pipeline primarily on the therapeutic areas of oncology as well as immunology and inflammation. Following the wind-down of its cell therapy operations, its pipeline centers on clinical-stage investigational assets such as GLPG3667, a selective kinase inhibitor being evaluated for autoimmune disorders. Its intended beneficiaries and end-users are patients facing severe medical diseases.

The company maintains its corporate headquarters and executive offices in Mechelen, Belgium. Historically operating across multiple regions, its ongoing streamlined organization maintains an operational presence and personnel in Mechelen, Chicago, and San Francisco following the closure of facility sites located in the United States, Switzerland, the Netherlands, and China. In addition, its commercial operations previously spanned fourteen European nations prior to business divestment activities.

Summary of the business section of Lakefront Biotherapeutics's latest annual report, written by StockData.

“As of December 31, 2025, we had 452 employees.”